Copyright Reports & Markets. All rights reserved.

Global Metastatic Melanoma Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Metastatic Melanoma Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Metastatic Melanoma Drug Market Size Growth Rate by Product
      • 1.4.2 AGI-134
      • 1.4.3 ALT-801
      • 1.4.4 ALT-803
      • 1.4.5 AMG-232
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Metastatic Melanoma Drug Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Metastatic Melanoma Drug Market Size
      • 2.1.1 Global Metastatic Melanoma Drug Revenue 2014-2025
      • 2.1.2 Global Metastatic Melanoma Drug Sales 2014-2025
    • 2.2 Metastatic Melanoma Drug Growth Rate by Regions
      • 2.2.1 Global Metastatic Melanoma Drug Sales by Regions
      • 2.2.2 Global Metastatic Melanoma Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Metastatic Melanoma Drug Sales by Manufacturers
      • 3.1.1 Metastatic Melanoma Drug Sales by Manufacturers
      • 3.1.2 Metastatic Melanoma Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Metastatic Melanoma Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Metastatic Melanoma Drug Revenue by Manufacturers
      • 3.2.1 Metastatic Melanoma Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Metastatic Melanoma Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Metastatic Melanoma Drug Price by Manufacturers
    • 3.4 Metastatic Melanoma Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Metastatic Melanoma Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Metastatic Melanoma Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Metastatic Melanoma Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Metastatic Melanoma Drug Sales by Product
    • 4.2 Global Metastatic Melanoma Drug Revenue by Product
    • 4.3 Metastatic Melanoma Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Metastatic Melanoma Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Metastatic Melanoma Drug by Countries
      • 6.1.1 North America Metastatic Melanoma Drug Sales by Countries
      • 6.1.2 North America Metastatic Melanoma Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Metastatic Melanoma Drug by Product
    • 6.3 North America Metastatic Melanoma Drug by End User

    7 Europe

    • 7.1 Europe Metastatic Melanoma Drug by Countries
      • 7.1.1 Europe Metastatic Melanoma Drug Sales by Countries
      • 7.1.2 Europe Metastatic Melanoma Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Metastatic Melanoma Drug by Product
    • 7.3 Europe Metastatic Melanoma Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Metastatic Melanoma Drug by Countries
      • 8.1.1 Asia Pacific Metastatic Melanoma Drug Sales by Countries
      • 8.1.2 Asia Pacific Metastatic Melanoma Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Metastatic Melanoma Drug by Product
    • 8.3 Asia Pacific Metastatic Melanoma Drug by End User

    9 Central & South America

    • 9.1 Central & South America Metastatic Melanoma Drug by Countries
      • 9.1.1 Central & South America Metastatic Melanoma Drug Sales by Countries
      • 9.1.2 Central & South America Metastatic Melanoma Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Metastatic Melanoma Drug by Product
    • 9.3 Central & South America Metastatic Melanoma Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Metastatic Melanoma Drug by Countries
      • 10.1.1 Middle East and Africa Metastatic Melanoma Drug Sales by Countries
      • 10.1.2 Middle East and Africa Metastatic Melanoma Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Metastatic Melanoma Drug by Product
    • 10.3 Middle East and Africa Metastatic Melanoma Drug by End User

    11 Company Profiles

    • 11.1 Merck & Co., Inc.
      • 11.1.1 Merck & Co., Inc. Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Merck & Co., Inc. Metastatic Melanoma Drug Products Offered
      • 11.1.5 Merck & Co., Inc. Recent Development
    • 11.2 Merck KGaA
      • 11.2.1 Merck KGaA Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Merck KGaA Metastatic Melanoma Drug Products Offered
      • 11.2.5 Merck KGaA Recent Development
    • 11.3 Millennium Pharmaceuticals, Inc.
      • 11.3.1 Millennium Pharmaceuticals, Inc. Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Products Offered
      • 11.3.5 Millennium Pharmaceuticals, Inc. Recent Development
    • 11.4 Morphotek, Inc.
      • 11.4.1 Morphotek, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Morphotek, Inc. Metastatic Melanoma Drug Products Offered
      • 11.4.5 Morphotek, Inc. Recent Development
    • 11.5 NewLink Genetics Corporation
      • 11.5.1 NewLink Genetics Corporation Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 NewLink Genetics Corporation Metastatic Melanoma Drug Products Offered
      • 11.5.5 NewLink Genetics Corporation Recent Development
    • 11.6 Novartis AG
      • 11.6.1 Novartis AG Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Novartis AG Metastatic Melanoma Drug Products Offered
      • 11.6.5 Novartis AG Recent Development
    • 11.7 Omeros Corporation
      • 11.7.1 Omeros Corporation Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Omeros Corporation Metastatic Melanoma Drug Products Offered
      • 11.7.5 Omeros Corporation Recent Development
    • 11.8 Oncolytics Biotech Inc.
      • 11.8.1 Oncolytics Biotech Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Products Offered
      • 11.8.5 Oncolytics Biotech Inc. Recent Development
    • 11.9 OncoSec Medical Inc.
      • 11.9.1 OncoSec Medical Inc. Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 OncoSec Medical Inc. Metastatic Melanoma Drug Products Offered
      • 11.9.5 OncoSec Medical Inc. Recent Development
    • 11.10 Ono Pharmaceutical Co., Ltd.
      • 11.10.1 Ono Pharmaceutical Co., Ltd. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Products Offered
      • 11.10.5 Ono Pharmaceutical Co., Ltd. Recent Development
    • 11.11 Pfizer Inc.
    • 11.12 Pharmis Biofarmaceutica, Lda.
    • 11.13 Philogen S.p.A.
    • 11.14 Plexxikon Inc.

    12 Future Forecast

    • 12.1 Metastatic Melanoma Drug Market Forecast by Regions
      • 12.1.1 Global Metastatic Melanoma Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Metastatic Melanoma Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Metastatic Melanoma Drug Market Forecast by Product
      • 12.2.1 Global Metastatic Melanoma Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Metastatic Melanoma Drug Revenue Forecast by Product 2019-2025
    • 12.3 Metastatic Melanoma Drug Market Forecast by End User
    • 12.4 North America Metastatic Melanoma Drug Forecast
    • 12.5 Europe Metastatic Melanoma Drug Forecast
    • 12.6 Asia Pacific Metastatic Melanoma Drug Forecast
    • 12.7 Central & South America Metastatic Melanoma Drug Forecast
    • 12.8 Middle East and Africa Metastatic Melanoma Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Metastatic Melanoma Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Metastatic Melanoma Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Metastatic Melanoma Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Metastatic Melanoma Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Metastatic Melanoma Drug in these regions.
      This research report categorizes the global Metastatic Melanoma Drug market by top players/brands, region, type and end user. This report also studies the global Metastatic Melanoma Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Merck & Co., Inc.
      Merck KGaA
      Millennium Pharmaceuticals, Inc.
      Morphotek, Inc.
      NewLink Genetics Corporation
      Novartis AG
      Omeros Corporation
      Oncolytics Biotech Inc.
      OncoSec Medical Inc.
      Ono Pharmaceutical Co., Ltd.
      Pfizer Inc.
      Pharmis Biofarmaceutica, Lda.
      Philogen S.p.A.
      Plexxikon Inc.

      Market size by Product
      AGI-134
      ALT-801
      ALT-803
      AMG-232
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Metastatic Melanoma Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Metastatic Melanoma Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Metastatic Melanoma Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Metastatic Melanoma Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Metastatic Melanoma Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Metastatic Melanoma Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now